These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34459972)

  • 1. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.
    Kim HI; Lim J; Shim JH
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2069-2077. PubMed ID: 34459972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
    Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
    Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
    Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.
    Chan SL; Mo FK; Johnson PJ; Hui EP; Ma BB; Ho WM; Lam KC; Chan AT; Mok TS; Yeo W
    J Clin Oncol; 2009 Jan; 27(3):446-52. PubMed ID: 19064965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
    J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
    Paul SB; Sahu P; Sreenivas V; Nadda N; Gamanagatti SR; Nayak B; Shalimar S; Acharya SK
    Scand J Gastroenterol; 2019 Sep; 54(9):1132-1137. PubMed ID: 31483691
    [No Abstract]   [Full Text] [Related]  

  • 11. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
    Riaz A; Ryu RK; Kulik LM; Mulcahy MF; Lewandowski RJ; Minocha J; Ibrahim SM; Sato KT; Baker T; Miller FH; Newman S; Omary R; Abecassis M; Benson AB; Salem R
    J Clin Oncol; 2009 Dec; 27(34):5734-42. PubMed ID: 19805671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
    J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
    Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
    BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between posttreatment α-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Wang X; Parrinello CM; Gossai A; Kim R; Magee K; Miksad RA
    Cancer; 2023 Jul; 129(13):2064-2074. PubMed ID: 36942492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
    Hsu WF; Wang HW; Chen CK; Lai HC; Chuang PH; Tsai MH; Su WP; Chen HY; Chu CS; Chou JW; Chen SH; Tsai TY; Hsiao WD; Lin CC; Huang GT; Lin JT; Peng CY
    Am J Cancer Res; 2021; 11(12):6173-6187. PubMed ID: 35018250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.
    Xu XS; Qu K; Liu C; Zhang YL; Liu J; Song YZ; Zhang P; Liu SN; Chang HL
    World J Gastroenterol; 2012 Dec; 18(48):7242-50. PubMed ID: 23326129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
    Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
    J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
    Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
    J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
    Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.